Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis.

4 m).[ 8 ] The RECORD-3 study also showed a trend toward longer PFS with initial sunitinib compared with everolimus (7.2 m vs. 5.1 m) in the 66 patients who belonged to the subset of NCC mRCC.[ 9 ] The ESPN crossover study, however, showed no difference in OS between initial sunitinib and everolimus (16.2 m vs. 14.9 m).[ 10 ] In this study, we report here the outcomes of NCC mRCC treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin (mTOR) inhibitors at our institute, a tertiary care referral cancer center in India.

also in 53,322 other papers